Scarica l'app Stockscreener
0.2904
2.06%
-0.0061
Pre-mercato:
.31
0.0196
+6.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$0.2965
Aprire:
$0.3
Volume 24 ore:
775.78K
Relative Volume:
0.54
Capitalizzazione di mercato:
$21.97M
Reddito:
-
Utile/perdita netta:
$-26.92M
Rapporto P/E:
-0.5694
EPS:
-0.51
Flusso di cassa netto:
$-18.92M
1 W Prestazione:
+13.97%
1M Prestazione:
+16.16%
6M Prestazione:
-68.02%
1 anno Prestazione:
-79.97%
Intervallo 1D:
$0.286
$0.307
Intervallo di 1 settimana:
$0.2501
$0.3111
Portata 52W:
$0.18
$2.39
Cel-Sci Corp. Stock (CVM) Company Profile
Nome
Cel-Sci Corp.
Settore
Industria
Telefono
703-506-9460
Indirizzo
8229 Boone Boulevard, Suite 802, Vienna, VA
Confronta CVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.2904 | 21.97M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-02 | Iniziato | Dawson James | Buy |
Cel-Sci Corp. Borsa (CVM) Ultime notizie
Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com
US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI
CEL-SCI to seek Saudi approval for cancer treatment - Investing.com
CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com
CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan
Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX
Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News
An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com
Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com
Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Yahoo Finance
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan
CEL-SCI advances in head and neck cancer treatment study - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance
CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market - Stock Titan
Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL.com
CVMCEL-SCI Corp Latest Stock News & Market Updates - Stock Titan
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
CEL-SCI advances Multikine study for head and neck cancer - Investing.com
CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance
Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - Stock Titan
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace
Cel-Sci Corp. Azioni (CVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):